US6821431029 - Common Stock
OMEROS CORP
NASDAQ:OMER (5/15/2024, 7:00:17 PM)
After market: 3.85 -0.32 (-7.67%)4.17
-0.03 (-0.71%)
Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 196 full-time employees. The company went IPO on 2009-10-08. The company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria, complement 3 (C3) glomerulopathy and one or more related indications.
OMEROS CORP
201 Elliott Avenue West
Seattle WASHINGTON 98119
P: 12066765000
CEO: Gregory A. Demopulos
Employees: 196
Website: https://www.omeros.com/
OMER stock results show that Omeros missed analyst estimates for earnings per share the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Omeros (NASDAQ:OMER) just reported results for the first quarter of 2024.Omeros...
Here you can normally see the latest stock twits on OMER, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: